SCHEMBL9890586

SCHEMBL9890586

c1ccc2c(c1)c1ccccc1n2-c1ccc2oc3ccc4oc5ccc(-c6cc(-c7ccc8oc9ccc%10oc%11ccc(-n%12c%13ccccc%13c%13ccccc%13%12)cc%11c%10c9c8c7)cc(-c7ccc8oc9ccc%10oc%11ccc(-n%12c%13ccccc%13c%13ccccc%13%12)cc%11c%10c9c8c7)c6)cc5c4c3c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PLA2G2A P14555 5/20 0.36
PLA2G4A P47712 5/20 0.36
PLA2G10 O15496 1/20 0.36
ALDH1A1 P00352 4/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
HSD17B10 Q99714 2/20 0.34
CASP3 P42574 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
POLB P06746 1/20 0.34
TSHR P16473 1/20 0.34
BRCA1 P38398 1/20 0.34
EDNRB P24530 1/20 0.33
EDNRA P25101 1/20 0.33
CHRNA7 P36544 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12811622 0.97 KDM4E (0.39) KDM4EATML3MBTL1PLA2G2APLA2G4A
SCHEMBL9890560 0.97 KDM4E (0.43) KDM4EATML3MBTL1PLA2G2APLA2G4A
SCHEMBL9890520 0.96 KDM4E (0.41) KDM4EATML3MBTL1PLA2G2APLA2G4A
SCHEMBL9890568 0.96 PLA2G2A (0.41) KDM4EATML3MBTL1PLA2G2APLA2G4A
SCHEMBL9890573 0.95 KDM4E (0.42) KDM4EATML3MBTL1PLA2G2APLA2G4A
SCHEMBL9890565 0.93 PLA2G2A (0.42) KDM4EATML3MBTL1PLA2G2APLA2G4A
SCHEMBL9890531 0.93 KDM4E (0.43) KDM4EATML3MBTL1PLA2G2APLA2G4A
SCHEMBL9890530 0.93 KDM4E (0.41) KDM4EATML3MBTL1PLA2G2APLA2G4A
SCHEMBL9890564 0.93 KDM4E (0.43) KDM4EATML3MBTL1PLA2G2APLA2G4A
SCHEMBL9890524 0.92 PLA2G2A (0.41) KDM4EATML3MBTL1PLA2G2APLA2G4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130020563-A1 POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2013-01-24 US disclosed
US-20130020563-A1 POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2013-01-24 US disclosed
US-8318323-B2 Polycyclic compounds and organic electroluminescence device employing the same IDEMITSU KOSAN CO., LTD. (JP) 2012-11-27 US disclosed
US-8318323-B2 Polycyclic compounds and organic electroluminescence device employing the same IDEMITSU KOSAN CO., LTD. (JP) 2012-11-27 US disclosed
US-20120138915-A1 ORGANIC ELECTROLUMINESCENCE DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2012-06-07 US disclosed
US-20120138915-A1 ORGANIC ELECTROLUMINESCENCE DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2012-06-07 US disclosed
US-20100012931-A1 POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130020563-A1 POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME KCNC1, EED, BMI1 KDM4E 990/4885ATM 3103/4885L3MBTL1 709/4885
US-20100012931-A1 POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME KCNC1, EED, BMI1 KDM4E 990/4885ATM 3103/4885L3MBTL1 709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.